BioSpring GmbH
Elena Kurzbach is a seasoned professional in the field of pharmaceutical biology and quality control, currently serving as the Quality Control Stability Manager at BioSpring GmbH since August 2021. Prior to this role, Elena worked as a Doctoral Student at Technische Universität Braunschweig from January 2015 to March 2021, focusing on establishing a plant production platform for specialized metabolites through transgenic carrot suspension cultures. Elena's experience includes multiple research and assistant positions at prestigious institutions such as the University of Heidelberg and De Montfort University. Elena holds a Dr. rer. nat. in Pharmaceutical Biology from Technische Universität Braunschweig, a Master of Science in Plant Molecular Biology, and a Bachelor of Science in Biology, with a foundational education completed at the Carl-Benz-Gymnasium in Ladenburg.
This person is not in any offices
BioSpring GmbH
BioSpring is a leading industry expert in oligonucleotide science and technology, specializing in high-quality cGMP manufacturing and analytics for commercial programs and clinical phases I-III, in addition to preclinical material supply and diagnostic manufacturing. We are a privately owned company of ~600 employees committed to providing expert support through all phases and regulatory filings, including highly flexible and customizable solutions to accelerate therapeutic programs through the entire drug development lifecycle. Headquartered in the center of Europe, in Frankfurt, Germany, we are an international company with a subsidiary in the United States and a local presence in Japan. Our global clients can rely on our quality and expertise, guided by our passion for innovation and more than 27 years of experience. Our aim is a highly collaborative partnership to unleash the full potential of our clients’ technology – making great strides and breakthroughs possible. We are driven by our desire for a healthier world. Restoring hope in patients living with debilitating diseases is our daily motivation to progress novel nucleic acid-based therapies to their commercial promise. Privacy notice: https://www.biospring.de/datenschutz-socialmedia/